Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared with empagliflozin QD in Type-2-diabetes-mellitus patients with mild to moderate hypertension

Trial Profile

A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared with empagliflozin QD in Type-2-diabetes-mellitus patients with mild to moderate hypertension

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Sotagliflozin (Primary) ; Empagliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Aug 2018 Planned End Date changed from 1 Oct 2018 to 7 Aug 2019.
    • 27 Aug 2018 Planned primary completion date changed from 1 Oct 2018 to 7 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top